Le 5 juin 2022, le Comité consultatif national sur les annexes de médicaments (CCNAM) a proposé les recommandations provisoires suivantes (disponibles qu’en anglais) :

• Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16% and less than or equal to 2.32% for not more than 7 days – in package sizes containing greater than 2.6g of diclofenac diethylamine be granted Schedule III status
• Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16% and less than or equal to 2.32% for not more than 7 days – in package sizes containing no more than 2.6g of diclofenac diethylamine be granted Unscheduled status
• Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16% for not more than 7 days remain Unscheduled

Ces recommandations ont été finalisées le 26 juillet 2022. Le conseil d’administration de l’ANORP a approuvé les recommandations provisoires en tenant compte des commentaires reçus au cours de la période d’examen de 30 jours. Les Annexes nationales de médicaments seront révisées en conséquence.